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Original Article
Surgical Outcomes and Prognostic Factors for 
T4 Gastric Cancers
Jong-Han Kim, You-Jin Jang, Sung-Soo Park, Seong-Heum Park, Seung-Joo Kim, Young-Jae Mok and 
Chong-Suk Kim, Department of Surgery, Korea University College of Medicine, Ansan City, South Korea.
PURPOSE: In locally advanced gastric carcinomas that have invaded adjacent organs, the prognosis is
poor. When combined resections are performed in T4 gastric cancers, a high morbidity rate is reported
and it is inconclusive as to whether or not there is an improvement in the survival rate. We investigated
surgical outcomes and analysed the prognostic factors for T4 gastric cancers.
PATIENTS AND METHODS: Between January 1992 and December 2000, 132 patients underwent 
surgery for T4 gastric cancer; they were divided into three groups: combined resections in group I, gas-
trectomy alone in group II, and resections not performed but palliative gastrojejunostomy or intraperi-
toneal chemotherapy in group III. Surgical outcomes and clinicopathologic factors were compared and
prognostic factors were evaluated.
RESULTS: Among the three groups, statistically significantly different factors were tumour location,
Borrmann type, tumour size, distant metastasis and peritoneal metastasis. The most commonly resected
organ was the transverse colon, and 14 post-operative morbidities developed. In the multivariate analysis,
the treatment group and curability were proved to be independent prognostic factors.
CONCLUSION: In patients with T4 gastric carcinoma, an aggressive surgical approach can be beneficial
when curative resection is performed. If curative resection is not possible, palliative resection can be 
performed for a better quality of life. [Asian J Surg 2009;32(4):198–204]
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Introduction
Gastric cancer is a second leading cause of death in 
the world, accounting 10% of newly diagnosed cancers.1
Although gastric cancer mortality has markedly declined
around the world, the overall 5-year survival rate for locally
advanced gastric carcinoma patients is below 20% and it 
is approximately 30% for these who undergo surgery. 
Even after a curative resection, only 30–50% of patients
are still alive after 5 years, with local and peritoneal recur-
rence being the main cause of treatment failure.2 Surgical
treatment for gastric carcinoma is currently considered as
the best approach for achieving curative outcomes.3 Lymph
node metastasis, depth of invasion, and tumour invasion
to adjacent organs (T4) are all believed to be independent
prognostic factors for gastric carcinoma.4 In locally ad-
vanced gastric cancer, especially when the adjacent organ
is invaded (T4), the prognosis is known to be poor because
curative resection is difficult and a high incidence of post-
operative morbidity and mortality is reported in other
studies.5–9 It is unclear whether combined resection can
improve the outcomes of surgery in patients with T4 
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gastric carcinoma, because it is difficult to completely
eliminate whole invading lesions, and post-operative
complications can sometimes be fatal.5,6,8–10 Recently, the
therapeutic role of palliative resection, namely non-curative
resection for locally advanced gastric cancer has been
debated in several study groups, and it is a problem more
complicated in T4 gastric cancers.7,11–15 In this study, we
retrospectively studied surgical outcomes and analysed
the prognostic factors for T4 gastric cancer patients to
investigate the significance of curative (R0) multi-organ
resection and palliative, that is, non-curative surgical
treatment.
Patients and Methods
From 1992 to 2000, 1499 gastric cancer patients under-
went surgical treatment at the Department of Surgery in
Korea University Hospital. Among these patients, 132
patients were diagnosed with clinical T4 gastric carcinoma
(cT4) that invaded adjacent organs, and surgical treat-
ment was performed. Of these patients, 56 cases (42.4%)
were histologically proved to be T4 gastric carcinoma
(pT4). According to the surgical therapeutic approaches,
the patients were divided into three groups: 34 patients
underwent combined other organ resections (group I), 45
patients received gastrectomy alone (group II), and resec-
tions were not performed but palliative gastrojejunos-
tomy or intraperitoneal chemotherapy were performed in
53 patients (group III). Combined resection with curative
intent was indicated for those patients with tumour inva-
sion of adjacent organs without distant metastasis or
peritoneal disseminations. Some palliative resections
were performed in patients with impending obstruction
or cancer bleeding signs that had resectable tumour bur-
dens without extensive peritoneal disseminations.
Among these three groups, the clinicopathologic vari-
ables, such as gender, age, type of gastrectomy, tumour
location, gross tumour type, histologic type, lymph node
stage and distant metastasis were examined and compared.
M1 was defined as comprising distant organ metastasis,
and advanced nodal involvement like para-aortic metas-
tasis and peritoneal metastasis. The curative (R0) resec-
tion was defined as the complete removal of cancer tissue
regardless of combined multi-organ resection with no
residual tumour macroscopically or microscopically. The
surgical outcomes such as post-operative morbidity and
curability were also evaluated.
In our surgical department, standard D2 lymph node
dissections were performed in curative resections and, in
selected cases, more extensive lymph node dissection,
such as D2 plus para-aortic lymph node dissection, was
performed with curative intent. However, we usually per-
formed D1 or lesser than D2 lymph node dissections 
in palliative cases. The prognostic factors for T4 gastric
cancers were evaluated in univariate survival analysis, and
Cox proportional multivariate survival analysis was 
performed to identify independent prognostic factors 
in these patients. The SPSS program version 13.0 for
Windows (SPSS Inc, Chicago, IL, USA) was used for all
statistical analyses. The chi-squared test was applied to
evaluate the difference in the proportions in the three
treatment groups. Analysis of variance (ANOVA) was used
to evaluate continuous variables, and all data are expressed
as means ± SD. The survival curves according to the sur-
gical treatment were constructed using Kaplan-Meier
method and compared using the log-rank test. Multivariate
analyses were performed using the Cox proportional 
hazard regression model. A value of p < 0.05 was consid-
ered statistically significant.
Results
Clinicopathologic features and outcomes
The clinicopathologic features of the 132 patients accord-
ing to treatment groups are depicted in Table 1. The sta-
tistically significantly different factors were tumour
location, Borrmann type, tumour size, M stage and peri-
toneal metastasis (Table 1). In group I and II patients, a
total of 43 curative (R0) resections (32.6%) were per-
formed. Twenty-six patients (76.5%) in group I were cured
by means of combined organ resection, however, only 17
cases (37.8%) in group II were cured by gastrectomy alone.
In group III, 23 patients received palliative gastrojejunos-
tomy but we could not perform any operative procedures,
and in 17 patients, intraperitoneal chemotherapy was
done. Combined adjacent organ resection was performed
in 34 cases in total (25%). The most common organ among
these was the transverse colon (15 cases), and multi-organ
resection was performed in 11 cases (Table 2). During
immediate post-operative periods, 14 cases of morbidity
were reported in the study groups, and there were no sig-
nificant differences according to the treatment groups
(Table 3). Also, no post-operative 30-day mortality was
reported in our study groups.
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Prognostic factors and survival analysis
In univariate survival analyses, the statistically significant
prognostic factors were histologic type, M stage, peritoneal
metastasis, curability and treatment groups (Table 4). In
multivariate analyses with these factors, the independent
significant prognostic factors were curability and treatment
groups according to surgical approaches (Table 5).
In survival analyses, the overall survival rate of all 
T4 patients was 27% at 3 years and 19.5% at 5 years. When
the survival curves were compared according to the 
treatment groups, there was no definite survival differ-
ence between group I and group II, but a marked differ-
ence between group III and the resection groups (groups I
and II) (Figure).
Discussion
In this study, the significantly different clinicopathologic
factors among the three treatment groups were tumour
location, Borrmann type, tumour size, and M stage, 
Table 1. Clinicopathologic features of T4 gastric cancer patients according to the surgical approaches
Group I (n= 34) Group II (n= 45) Group III (n= 53) p
Gender 0.562
Male 21 (61.8%) 31 (68.9%) 31 (58.5%)
Female 13 (38.2%) 14 (31.1%) 22 (41.5%)
Age (mean ± SD) 55.76 ± 11.85 57.96 ± 12.52 55.02 ± 12.51 0.489
Type of gastrectomy 0.161
Total 22 (64.7%) 22 (48.9%)
Subtotal 12 (35.3%) 23 (51.1%)
Tumour location 0.021*
Upper 1/3 5 (14.7%) 1 (2.2%) 1 (1.9%)
Middle 1/3 8 (23.5%) 7 (15.6%) 7 (13.2%)
Lower 1/3 13 (38.2%) 29 (64.4%) 26 (49.1%)
Diffuse 8 (23.5%) 8 (17.8%) 19 (35.8%)
Borrmann type 0.033*
Type II 0 (0.0%) 3 (6.7%) 8 (15.1%)
Type III 23 (67.6%) 32 (71.1%) 25 (47.2%)
Type IV 11 (32.4%) 10 (22.2%) 20 (37.7%)
Tumour size (mean±SD, cm) 6.84 ± 2.99 5.89 ± 2.63 8.30 ± 3.38 0.001*
Histologic type 0.054
Differentiated 15 (44.1%) 19 (42.2%) 12 (22.6%)
Undifferentiated 19 (55.9%) 26 (57.8%) 41 (77.4%)
N stage 0.286
N0 3 (8.8%) 6 (13.3%)
N1 (1~6) 16 (47.1%) 12 (26.7%)
N2 (7~15) 9 (25.8%) 14 (31.1%)
N3 ( ≥ 16) 6 (17.6%) 13 (28.9%)
M stage < 0.001*
M0 (absent) 21 (61.8%) 23 (51.1%) 7 (13.2%)
M1 (present) 13 (38.2%) 22 (48.9%) 46 (86.8%)
Peritoneal metastasis < 0.001*
P0 (absent) 28 (82.4%) 30 (66.7%) 13 (24.5%)
P1 (localized) 5 (14.7%) 11 (24.4%) 34 (64.2%)
P2 (disseminated) 1 (2.9%) 4 (8.9%) 6 (11.3%)
*p<0.05. Group I: patients with combined resection; Group II: patients with gastrectomy alone; Group III: patients with no resection.
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especially peritoneal metastasis. In our study, the main
tumour location was in the lower third in all three treat-
ment groups of T4 gastric cancers. This was the common
finding for T4 gastric cancer patients in Eastern coun-
tries,  but in Western countries, a high incidence of proxi-
mal stomach and gastroesophageal junction tumour was
reported in T4 gastric cancer patients.16,17 Also, in our study,
diffuse tumour location and Borrmann type IV gastric
cancer comprised a relatively large proportion in group III.
This phenomenon could be explained by the high inci-
dence of peritoneal seeding in Borrmann IV gastric cancer,
that is, linitis plastica.18 When gastroenterologic surgeons
encounter disseminated peritoneal seeding in laparo-
tomies, they usually do not perform resections, but rather
palliative procedures including bypass surgery (gastroje-
junostomy) and intraperitoneal chemotherapy.19,20
Therefore, the proportion of cases with localised (P1) and
disseminated (P2) peritoneal seeding was relatively low in
groups I and II when compared to group III. Occasionally,
we performed gastrectomy in localised cases for palliative
treatment, but the result was poor. In some reports,
tumour size in gastric cancer has been shown to be a sig-
nificant prognostic factor, and large gastric cancers with
diameter more than 8 cm have more aggressive behaviour
and frequent peritoneal recurrences.21,22 In our study
groups, the average diameter of the tumours in group III
was about 8.3 cm, which corresponds to the criteria of a
large gastric cancer; therefore, the rate of distant metasta-
sis, including peritoneal dissemination, was higher than
in the other groups and statistically different compared
with the other groups. In this study, we performed com-
bined multi-organ resection in 34 cases in group I, com-
prising 25% of all cases, and curative resections were
performed in 26 patients (76.5%). Interestingly, 17
patients (37.8%) in group II could acquire curability by
way of gastrectomy alone. Although the gastric cancer was
found to have invaded adjacent organs in laparotomy
(cT4), the final pathologic result was not (pathological
T3), therefore accurate peri-operative gastric cancer stag-
ing is a difficult problem.11,23 In fact, other studies6,23
reported that pathological T4 was confirmed in 38–56%
of cases after combined resection was performed in clini-
cal T4 gastric cancers. These findings can be explained by
the possibility that macroscopic invasion seen during
operation is identified as inflammatory adhesion at 
the final pathologic analysis, and such a phenomenon
might have occurred in group II in our cases. In group I,
the most common combined organs resected were the 
transverse colon as well as the spleen and pancreas. In gas-
tric cancers located in the middle and lower third, com-
bined resection might be necessary to achieve curative
Table 3. Morbidities in surgical treatment for T4 gastric cancer patients
Treatment group Type of complication Combined resected organs No. of patients
Group I Anastomotic leakage/renal complication Transverse colon 1
Pulmonary complication Spleen, pancreas, T-colon 1
Peritonitis Transverse colon 1
Anastomotic leakage/pancreatic fistula Spleen, pancreas, T-colon 1
Group II Wound failure None 2
Anastomotic leakage None 2
Post-operative bleeding None 1
Group III Wound failure None 3
Paralytic ileus None 1
General weakness None 1
Table 2. Patterns of combined organ resection in T4 gastric cancer
patients
Resected organs No. of patients (%)
No resection 98 (75.0)
Transverse colon 15 (11.4)
Spleen + pancreas 6 (3.8)
(pancreaticosplenectomy)
Spleen 4 (3.0)
Liver 4 (3.0)
Spleen + pancreas + transverse colon 3 (2.3)
Transverse colon + pancreas 1 (0.8)
Gallbladder 1 (0.8)
Total 132 (100)
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goals when a cancer invades the posterior wall of the
stomach, infiltrating the transverse colon and its meso-
colon. There is a study reporting that patients with colon
or mesocolon invasion had a significant survival advan-
tage over those with other organ invasions in univariate
analysis, however it was not a significant variable in the
multivariate analysis.24 Some other studies10,25 report the
spleen and pancreas as the commonly resected adjacent
organs, and we performed multi-organ resections in sel-
ected cases including splenectomies with distal pancrea-
tectomies. When outcomes of patients who underwent
gastrectomies alone, or together with splenectomies or
Table 4. Univariate analyses of prognostic factors in T4 gastric cancer patients
Variables No. of patients 5-yr survival rate (%) p
Gender (male/female) NS
Age (yr) NS
Type of gastrectomy (total/subtotal) NS
Tumour location (upper/middle/lower 1/3/entire) NS
Borrmann type (Borrmann II/III/IV) NS
Tumour size (cm) NS
N stage (N0/1/2) NS
M stage 0.007*
M0 (no metastasis) 51 27.6
M1 (distant metastasis) 81 16.0
Histologic type 0.019*
Differentiated 46 23.7
Undifferentiated 86 11.8
Peritoneal metastasis
P0 (no metastasis) 71 26.9 0.003*
P1 (localized metastasis) 50 13.7
P2 (disseminated metastasis) 11 10.1
Curability < 0.001*
R0 resection 43 46.0
R1 resection 15 13.3
R2 resection 74 7.0
Treatment group < 0.001*
Group I 34 37.8
Group II 45 29.4
Group III 53 1.9*
*p<0.05. Group I: patients with combined resection; Group II: patients with gastrectomy alone; Group III: patients with no resection.
Table 5. Multivariate analyses of independent prognostic factors in T4 gastric cancer patients
Prognostic factors Relative risk 95% CI p
Treatment group (group I/II/III) 2.383 1.006–5.649 0.049*
Peritoneal metastasis (P0/1/2) 0.615 0.151–2.497 0.584
Lymph node dissection (N0/1/2) 1.585 0.676–3.717 0.236
Curability (R0/1/2) 1.771 0.699–4.486 0.006*
M stage (distant metastasis) 1.840 0.761–4.451 0.176
Histologic type (diff/undiff) 0.677 0.254–1.801 0.435
*p< 0.05.
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pancreaticosplenectomies were retrospectively evaluated,
the survival benefit was not demonstrated and overall
complications including infectious complications were
common.26,27 Dhar et al24 proposed that removal of the
spleen along with the organs invaded could produce the
best outcome with an acceptable mortality in the treat-
ment of T4 gastric carcinoma. We also performed gastrec-
tomy along with pancreaticosplenectomy in selected cases
and acquired curability with few post-operative problems.
In our series, a total of 14 postoperative complications
(10.6%) were reported and no mortality was found. It 
was a strikingly favourable outcome when compared 
with other reports.9,10,25 This favourable result could be
explained by our study design which included patients
who could not undergo gastrectomies but could undergo
palliative procedures (group III) and suffered from mini-
mal surgical stress. However, there was no significant dif-
ference in post-operative morbidity between resection and
non-resection patients. Furthermore, there was no differ-
ence in post-operative morbidity between combined resec-
tion and the gastrectomy alone group. In other reports,
mortality and morbidity rates associated with palliative
resection have been shown not to be statistically signifi-
cantly different from patients who underwent curative
gastrectomy.14 Based on these considerations, we suggest
that extended gastrectomy with additional organ resec-
tion can be performed with minimal morbidity and can
improve the chance of overall survival in patients with T4
gastric carcinoma. In our study groups, we achieved bet-
ter surgical outcomes for T4 gastric cancers when curative
resection was performed. When the surgical approaches
were divided into three groups, en bloc resection of the
carcinoma including gastrectomy with combined organ
resection was shown to be a better surgical approach in
locally advanced T4 gastric cancer patients.
In our study, clinical data were retrospectively collected
and analysed in an intention-to-treat manner. Therefore,
better surgical outcomes could be achieved when curative
resection was performed in which there might be the
result of selection bias rather than surgical management.
Patients with far advanced gastric cancer are not com-
monly managed with surgical resection, and effective 
palliation can usually be accomplished with systemic che-
motherapy, endoscopic stenting, or surgical bypass proce-
dures.14,15 The importance of palliative resection in more
advanced gastric cancer is still debated, especially in T4 and
stage IV gastric cancers.7,14,15 In recent reports, gastrectomy
in addition to palliative resection proved to be valuable for
achieving survival benefit in T4 gastric cancer patients.7,14,15
In the present study, it is of interest to observe that multi-
variate analysis revealed that curative resection and the
treatment group, according to the surgical approach,
were significant independent prognostic factors, thus
showing that the long-term surgical outcome for gastric
carcinoma patients with adjacent invaded organs (T4) was
better with resection than without resection. Although
curative resection was not performed, palliative gastric
resection can be applicable to such more advanced gastric
cancer patients in terms of survival benefit and for a bet-
ter quality of life.
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